Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Johnson & Johnson

Sales to Customers

Sales to Customers %Chg

Sales to Customers Common Size

Cost of Products Sold

Cost of Products Sold %Chg

Cost of Products Sold Common Size

Gross Profit

Gross Profit %Chg

Gross Profit Common Size

Selling, Marketing and Administrative Expenses

Selling, Marketing and Administrative Expenses %Chg

Selling, Marketing and Administrative Expenses Common Size

Research and Development Expense

Research and Development Expense %Chg

Research and Development Expense Common Size

In-Process Research and Development Impairments

In-Process Research and Development Impairments %Chg

In-Process Research and Development Impairments Common Size

Total Expenses

Total Expenses %Chg

Total Expenses Common Size

Interest Income

Interest Income %Chg

Interest Income Common Size

Interest Expense, Net of Portion Capitalized

Interest Expense, Net of Portion Capitalized %Chg

Interest Expense, Net of Portion Capitalized Common Size

Other Expense, Net

Other Expense, Net %Chg

Other Expense, Net Common Size

Add: Net Loss Attributable to Noncontrolling Interest

Add: Net Loss Attributable to Noncontrolling Interest %Chg

Add: Net Loss Attributable to Noncontrolling Interest Common Size

Net Earnings Attributable to Johnson & Johnson

Net Earnings Attributable to Johnson & Johnson %Chg

Net Earnings Attributable to Johnson & Johnson Common Size

Restructuring

Restructuring %Chg

Restructuring Common Size

Earnings Before Provision for Taxes on Income

Earnings Before Provision for Taxes on Income %Chg

Earnings Before Provision for Taxes on Income Common Size

Provision for Taxes on Income

Provision for Taxes on Income %Chg

Provision for Taxes on Income Common Size

Net Earnings from Continuing Operations

Net Earnings from Continuing Operations %Chg

Net Earnings from Continuing Operations Common Size

Net Earnings from Discontinued Operations, Net of Tax

Net Earnings from Discontinued Operations, Net of Tax %Chg

Net Earnings from Discontinued Operations, Net of Tax Common Size

Net Earnings

Net Earnings %Chg

Net Earnings Common Size

Continuing Operations - Basic

Continuing Operations - Basic %Chg

Continuing Operations - Basic Common Size

Discontinued Operations - Basic

Discontinued Operations - Basic %Chg

Discontinued Operations - Basic Common Size

Basic

Basic %Chg

Basic Common Size

Net Earnings per Share from Continuing Operations

Net Earnings per Share from Continuing Operations %Chg

Net Earnings per Share from Continuing Operations Common Size

Net Earnings per Share from Discontinued Operations

Net Earnings per Share from Discontinued Operations %Chg

Net Earnings per Share from Discontinued Operations Common Size

Diluted

Diluted %Chg

Diluted Common Size

Cash Dividends per Share

Cash Dividends per Share %Chg

Cash Dividends per Share Common Size

Total Revenues

Total Revenues %Chg

Total Revenues Common Size

Cost of Sales

Cost of Sales %Chg

Cost of Sales Common Size

Gross Profit Margin

Gross Profit Margin %Chg

Gross Profit Margin Common Size

Selling, General & Administrative Expenses

Selling, General & Administrative Expenses %Chg

Selling, General & Administrative Expenses Common Size

Research & Development Expenses

Research & Development Expenses %Chg

Research & Development Expenses Common Size

Other Operating Expenses

Other Operating Expenses %Chg

Other Operating Expenses Common Size

Operating Profit

Operating Profit %Chg

Operating Profit Common Size

Operating Margin

Operating Margin %Chg

Operating Margin Common Size

Interest and Investment Income

Interest and Investment Income %Chg

Interest and Investment Income Common Size

Interest Expense

Interest Expense %Chg

Interest Expense Common Size

Non-Operating Income

Non-Operating Income %Chg

Non-Operating Income Common Size

Total Non-Operating Income

Total Non-Operating Income %Chg

Total Non-Operating Income Common Size

Income Before Provision for Income Taxes

Income Before Provision for Income Taxes %Chg

Income Before Provision for Income Taxes Common Size

Provision for Income Taxes

Provision for Income Taxes %Chg

Provision for Income Taxes Common Size

Consolidated Net Income

Consolidated Net Income %Chg

Consolidated Net Income Common Size

Net Income Attributable to Minority Interests and Other

Net Income Attributable to Minority Interests and Other %Chg

Net Income Attributable to Minority Interests and Other Common Size

Net Income Attributable to Discontinued Operations

Net Income Attributable to Discontinued Operations %Chg

Net Income Attributable to Discontinued Operations Common Size

Net Income Attributable to Common Shareholders

Revenue

EBIT

EBITDA

CapEx

Net Interest Income

Assets

Adjusted EBITDA

Adjusted Net Income

Net Revenue

Net Income

Average Assets

Adjusted EBIT

Adjusted Revenue

Adjusted EBT

Adjusted Funds From Operations

Income Statement	LTM	Dec '24	Dec '23	Jan '23	Jan '22	Jan '21	Dec '19	Dec '18	Dec '17	Jan '17	Jan '16
Total Revenues	92,149	88,821	85,159	79,990	78,740	82,584	82,059	81,581	76,450	71,890	70,074
Total Revenues %Chg	5.1%	4.3%	6.5%	1.6%	-4.7%	0.6%	0.6%	6.7%	6.3%	2.6%	-5.7%
Sales to Customers
Cost of Sales	—	27,471	26,553	24,596	23,402	28,427	27,556	27,091	25,439	21,789	21,536
Cost of Products Sold
Gross Profit	92,149	61,350	58,606	55,394	55,338	54,157	54,503	54,490	51,011	50,101	48,538
Gross Profit
Gross Profit Margin	100%	69.1%	68.8%	69.3%	70.3%	65.6%	66.4%	66.8%	66.7%	69.7%	69.3%
Selling, General & Administrative Expenses	—	22,869	21,512	20,246	20,118	22,084	22,178	22,540	21,520	20,067	21,203
Selling, Marketing and Administrative Expenses
Research & Development Expenses	—	17,232	15,085	14,135	14,277	12,159	11,355	10,775	10,594	9,143	9,046
Research and Development Expense
Other Operating Expenses	186	445	802	1,058	1,109	428	1,156	1,377	717	520	733
In-Process Research and Development Impairments
Restructuring
Operating Profit	91,963	20,804	21,207	19,955	19,834	19,486	19,814	19,798	18,180	20,371	17,556
Operating Margin	99.8%	23.4%	24.9%	24.9%	25.2%	23.6%	24.1%	24.3%	23.8%	28.3%	25.1%
Interest and Investment Income	—	1,332	1,261	490	53	111	357	611	385	368	128
Interest Income
Interest Expense	—	-755	-772	-276	-183	-201	-318	-1,005	-934	-726	-552
Interest Expense, Net of Portion Capitalized
Non-Operating Income	—	-4,694	-6,634	-810	-526	-2,899	-2,525	-1,405	42	-210	2,064
Other Expense, Net
Total Non-Operating Income	—	-4,117	-6,145	-596	-656	-2,989	-2,486	-1,799	-507	-568	1,640
Income Before Provision for Income Taxes	91,963	16,687	15,062	19,359	19,178	16,497	17,328	17,999	17,673	19,803	19,196
Earnings Before Provision for Taxes on Income
Provision for Income Taxes	—	2,621	1,736	2,989	1,377	1,783	2,209	2,702	16,373	3,263	3,787
Provision for Taxes on Income
Consolidated Net Income	91,963	14,066	13,326	16,370	17,801	14,714	15,119	15,297	1,300	16,540	15,409
Net Earnings from Continuing Operations
Net Income Attributable to Minority Interests and Other	—	—	—	—	—	—	—	—	—	—	—
Add: Net Loss Attributable to Noncontrolling Interest
Net Income Attributable to Discontinued Operations	—	—	21,827	1,571	3,077	—	—	—	—	—	—
Net Earnings from Discontinued Operations, Net of Tax
Net Income Attributable to Common Shareholders	91,963	14,066	35,153	17,941	20,878	14,714	15,119	15,297	1,300	16,540	15,409
Net Earnings
Basic EPS	10.4	5.8	13.9	6.8	7.9	5.6	5.7	5.7	0.5	6	5.6
Diluted EPS	10.4	5.8	13.7	6.7	7.8	5.5	5.6	5.6	0.5	5.9	5.5
Basic Weighted Average Shares Outstanding	2,412.2	2,407.3	2,533.5	2,625.2	2,632.1	2,632.8	2,645.1	2,681.5	2,692	2,737.3	2,771.8
Total Shares Outstanding	2,409.3	2,406.9	2,407.2	2,613.6	2,629	2,632.5	2,632.5	2,662.3	2,682.5	2,706.5	2,755.2
Diluted Weighted Average Shares Outstanding	2,424.7	2,429.4	2,560.4	2,663.9	2,674	2,670.7	2,684.3	2,728.7	2,745.3	2,788.9	2,812.9
EBITDA	99,351	28,143	28,693	26,925	27,224	26,717	26,823	26,727	23,822	24,125	21,302
Effective Tax Rate	—	15.7%	11.5%	15.4%	7.2%	10.8%	12.7%	15%	92.6%	16.5%	19.7%